Fujifilm to Double Production Capacity for COVID -19 Treatments

Fujifilm said it plans to invest $928 million to double production capacity at its biologics manufacturing facility in Denmark to supply bulk drug substances for future COVID-19 therapies and other products.

The investment will allow the company’s Danish subsidiary, Fujifilm Diosynth Biotechnologies, to scale up production. The contract development and manufacturing organization will supply bulk biologics to other drugmakers. — Jordan Williams